Neoadjuvant or preoperative chemotherapy is the preferred treatment for locally advanced, inflammatory and early-stage high-risk breast cancers. Patients with locally advanced breast cancers are candidates for neoadjuvant therapy because their tumours are often not amenable to resection. On the other hand, patients are candidates for neoadjuvant chemotherapy if the breast-conserving surgery is not possible. At present, anthracycline-and taxane-based chemotherapy regimens remain as the cornerstone for neoadjuvant therapy in early breast cancer, but there is a clear need for effective therapies in high-risk, early-stage patients. A number of chemotherapeutic and targeted therapies have been evaluated in clinical trials with varying results. The US Food and Drug Administration (FDA) has recently approved pertuzumab in combination with trastuzumab and cytotoxic chemotherapy as a neoadjuvant therapy option for HER2-positive breast cancer. This article reviews the neoadjuvant chemotherapeutic and targeted therapies options for early-stage, high-risk breast cancer. Possible role of molecular subtyping in triple-negative breast cancer is also described.
According to the World Health Organization (WHO), cancer-related mortalities reach 7.9 million worldwide each year.
1 Among women, breast cancer is one of the most common cancers globally. Despite advances in early detection and understanding on the molecular pathogenesis of breast cancer, approximately 30 % of patients with early-stage breast cancer experience recurrent disease. 2 Systemic treatment of breast cancer includes cytotoxic chemotherapy, endocrine (or hormonal) therapy and targeted therapy. These therapeutic agents are used in the adjuvant (post-surgical), neoadjuvant (pre-surgical) and metastatic settings.
Neoadjuvant therapy (also referred to as preoperative, pre-surgical, induction or primary systemic therapy) is the systemic treatment of breast cancer in the preoperative setting with curative intent. It was first evaluated more than 30 years ago for the treatment of locally advanced, inflammatory (a subtype of locally advanced breast cancer) and inoperable breast cancers. 3 It is now increasingly used in patients with operable disease. 3 The primary objective of the neoadjuvant therapy is to improve surgical outcomes [3] [4] [5] in patients for whom a primary surgical approach is technically not feasible and in patients with operable breast cancer who desire breast conservation. Second, neoadjuvant therapy decreases the need for complete axillary lymph node dissection. [6] [7] [8] It also allows an early evaluation of the systemic therapy. Third, neoadjuvant therapy gives clinicians an opportunity to obtain tumour specimens prior to and during the preoperative treatment, thus enabling researchers to investigate emerging drug therapies and predictive biomarkers. 7, 8 Recently, following the announcement by the US Food and Drug Administration (FDA) 9 that it will consider neoadjuvant randomised trials for accelerated drug approval in early breast cancer, there has been a marked increase in clinical trials with novel agents in the neoadjuvant setting. This review focuses on the current and emerging neoadjuvant chemotherapies and targeted therapies for early-stage, high-risk 9 (defined as 20-25 % risk of recurrence or death at 5 years) breast cancer.
Patient Selection
Neoadjuvant chemotherapy is the preferred treatment for locally advanced and inflammatory breast cancer. According to the American Joint Committee on Cancer, 10 locally advanced breast cancer is a stage III disease. Clinically, locally advanced breast cancer includes tumours that are localised to the breast tissue without regional nodal involvement, and may also include tumour sizes greater than 5 cm in diameter, or tumours of any size with overlying oedema, chest-wall fixation, skin infiltration or inflammatory features. Among these forms of locally advanced breast cancer, only clinical stage IIIA (T0N2M0; T1-3N2M0) is considered surgically resectable; whereas clinical stage IIIB (T4N0-2M0) and stage IIIC (any TN3M0) are considered unresectable or inoperable. 11 Patients with locally advanced breast cancer IIIB-C are candidates for neoadjuvant therapy. The histologically proved complete response following neoadjuvant therapy, i.e. the absence of invasive and non-invasive tumour in the breast tissue and lymph nodes (ypT0ypN0), confirmed by pathology, is known as the pathological complete response (pCR). 10 It has been widely used as a surrogate marker for disease response and is an indication for complete eradication of distant micrometastasis or residual disease.
11 It was first observed in patients with locally advanced breast cancer 14 and was subsequently confirmed in randomised trials in patients with operable disease.
14 However, the definition of pCR and the methods of assessment varied across clinical trials. [15] [16] [17] [18] [19] [20] [21] [22] Therefore, pCR alone cannot be applied as a predictor for long-term disease outcome. It is important to consider tumour involvement in both breast tissue and lymph nodes for pCR since the presence of residual disease in lymph nodes after neoadjuvant therapy may affect disease-free survival (DFS) and overall survival (OS). 23, 24 Of note, ductal carcinoma in situ (DCIS) does not require pCR since the presence of residual disease in DCIS does not affect DFS or OS. 25, 26 Neoadjuvant chemotherapy for locally advanced breast cancer is generally anthracycline-or taxane-based (see Table 1 ). At present, approximately 20 % of patients [14] [15] [16] [17] 23 achieve pCR after an appropriate neoadjuvant regimen. Randomised trials 20, 27 showed that non-anthracycline and anthracycline-containing regimens are considered equally efficacious regardless of whether they are given pre-or postoperatively. Equally, long-term efficacy had been demonstrated in the National Surgical Adjuvant Breast and Bowel Project (NSABP) trial in which docetaxel was administered either pre-or postoperatively. 28 An important caveat is, if the goal of therapy is to treat operable breast cancer, then any patient who is indicated for adjuvant therapy should also be offered neoadjuvant therapy.
14 Current US National Comprehensive Cancer Network (NCCN) guidelines 29 state that preoperative chemotherapy is not indicated unless invasive breast cancer is confirmed.
Cytotoxic Chemotherapy Principle and Options
In the last two decades, the potential benefits of preoperative (neoadjuvant) versus postoperative (adjuvant) chemotherapy have been tested in terms of DFS and OS. A recent meta-analysis 26 of nine randomised trials involving a total of 3,946 patients reported no differences in death, disease progression or distant recurrence between randomised arms. However, there is significant risk of locoregional recurrence after neoadjuvant chemotherapy, with odds ratio of 1.22
(95 % confidence interval [CI] 1.04-1.43). This significant risk is confined to trials with an excess of patients in the neoadjuvant arm that avoided surgery altogether, thus implicating that pCR is not a safe indicator for response since patients may proceed directly to radiation therapy. In fact, the NSABP B-27 trial 28 showed that, although pCR increased from 13.7 to 26.1 % (p<0.01) when four cycles of neoadjuvant docetaxel were added to four cycles of doxorubicin and cyclophosphamide (AC) alone (n=1,609), the rates on disease-free survival (DFS) and overall survival (OS) were no different in these two arms. Thus, broad acceptance of pCR as a long-term surrogate marker for DFS and OS requires formal comparison with parallel, conventional trials. The NSABP B-27 appears to challenge the validity of using a primary tumour response as the sole predictor for therapeutic effect. Nevertheless, improved pCR 29 has been demonstrated in certain subgroups (e.g. patients with triple-negative disease, HER2-positive disease or receiving targeted therapies).
Interestingly, the role of some non-traditional agents (e.g. capecitabine, gemcitabine) was studied in taxane and anthracycline-based regimens.
In the GeparQuattro trial, 30 1,421 patients received four cycles of neoadjuvant epirubicin and cyclophosphamide (EC) were randomised to: (1) four cycles of docetaxel; (2) four cycles of docetaxel and capecitabine; and (3) four cycles of docetaxel followed by capecitabine.
Results demonstrated that concurrent (but not sequential) treatment of docetaxel and capecitabine did not lead to significant improvement in pCR or breast-conservation rates. There was increased toxicity such as diarrhoea, nail changes and hand-foot syndrome. In general, poor or non-responders to the first-line taxane or anthracycline-based regimens are either switched to second-line chemotherapy or proceed directly to surgery. However, even with a pCR, surgery is still indicated, since the risk of residual microscopic disease is high. 4, 7 The NSABP B-18 trial 5 is the largest trial to date to investigate neoadjuvant chemotherapy. A total of 1,523 patients with T1 to T3 and N0 to N1 disease were randomised to receive preoperative AC versus postoperative AC for four cycles. In addition to using traditional response criteria, patients who had a complete response also underwent histology analysis for pCR. After a 9-year follow-up, investigators reported no significant difference in DFS and OS between these two groups. Furthermore, there was a significant association between pCR and outcome: patients with a pCR had a 50 % reduction in the risk of death compared with the overall population (relative risk 0.5, 95 % CI 0.32-0.78). The rate of pCR was higher in the group of AC added with docetaxel compared with the AC group (26.1 % versus 12.9 %; p<0.0001).
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The effect of weekly paclitaxel versus the standard every-3-week paclitaxel was evaluated in a phase III randomised trial. 31 Results showed that weekly paclitaxel had a statistically significant benefit in improvement of pCR compared with every-3-week paclitaxel. For N1 patients, the pCR was 28 % with weekly paclitaxel compared with 13.7 % with every-3-week paclitaxel (see Table 2 ).
Neoadjuvant Therapy for Early-stage, High-risk Breast Cancer
Recently, a meta-analysis of the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) by Cortazar and colleagues 32 suggested that patients who attain pCR have a more favourable long-term outcome such as event-free survival (EFS) and OS. The association of pCR with EFS and OS is stronger in patients with aggressive tumour types (HER2-overexpressed disease and triple-negative tumours) compared with the less-aggressive tumour types (hormone receptor-positive and lowgrade tumours). However, the magnitude of pCR improvement is not predictive of long-term clinical benefit, possibly due to low pCR rates, the heterogeneity of the population or the lack of correlation between pCR and EFS and OS. In a recent meta-analysis 33 of seven randomised trials in 6,377 patients with primary breast cancer who received anthracyclineand taxane-based neoadjuvant chemotherapies, pCR is a good surrogate endpoint for patients with triple-negative, HER2-negative disease. [36] [37] [38] In general, TNBC is associated with a poor prognosis of increased relapse and decreased OS. 39 At present, there is no targeted therapy available for TNBC. Cytotoxic chemotherapy, specifically anthracycline-and taxanebased regimens, remains as the current standard. 14 The aggressive nature of TNBC may be due to an increased expression of vascular endothelial growth factor (VEGF), which contributes to increased tumour proliferation through angiogenesis. 40 In the multicentre GeparQuinto study, 41 researchers investigated the use of bevacizumab with chemotherapy in the neoadjuvant setting for patients with TNBC. The primary objective was to measure the pCR after neoadjuvant chemotherapy with or without bevacizumab (B). All Results demonstrated that the addition of capecitabine or gemcitabine did not increase the rate of pCR, and there was no significant difference among the three chemotherapy regimens. This negative result was not surprising since similar findings had been reported in the GeparQuattro trial 30 and another study. 44 Furthermore, subgroup analyses of tumour size, nodal status, hormonal receptor status, age and tumour grade did not show significant differences between the three chemotherapy regimens. Notably, patients in the hormone receptor-positive subset had a statistically significant incremental increase in pCR with the addition of bevacizumab (11.1 % without bevacizumab versus 16.8 % with bevacizumab; p=0.03) than patients in the hormone receptor-negative subset. This result was in contrast to the German GeparQuinto study 41 in which the TNBC (hormone receptor negativity was defined by less than 10 % of immunostaining) patients had a significant pCR rate with bevacizumab. In addition, in the GeparQuinto trial, bevacizumab was added after four cycles of EC and before surgery. But in the NSABP-40 study, patients with T4 tumours were excluded and bevacizumab was administered for the first six cycles only.
Triple-negative Disease
Further analysis of the NSABP-40 study showed that the rate of pCR was significantly increased when bevacizumab was added to the docetaxelcapecitabine regimen (36.1 % versus 23.5 %; p=0.009). However, bevacizumab use was associated with increased rates of hypertension, mucositis, hand-foot syndrome and a statistically significant increase in grade 3 and 4 left ventricular dysfunction (<1 % versus 1 %; p=0.02).
To conclude, the use of anti-VEGF agent must be balanced by its riskbenefit ratio and current use cannot be recommended outside of clinical trials. Long-term study is warranted to determine if there is any significant improvement in OS.
HER2 Targeted or Directed Therapy
For patients with HER-2 positive breast cancer, current FDA approved neoadjuvant therapy options include: (1) trastuzumab and pertuzumab in combination with cytotoxic chemotherapy; (2) trastuzumab as a single agent or in combination with cytotoxic chemotherapy. Lapatinib, a dual HER2/EGFR tyrosine kinase inhibitor, currently FDA approved for metastatic therapy, had been used preoperatively in combination with trastuzumab in clinical trials. 45, 46 In standard neoadjuvant therapies for HER2-positive breast cancer, trastuzumab is typically combined with the taxane portion of systemic therapy, given the increased risk of cardiac toxicity when combined with anthracyclines. Nonetheless, a trial from MD Anderson Cancer Center in the US demonstrated the safe addition of epirubicin to trastuzumab. 47 Of note, the combination of anthracycline and anti-HER2 therapy is a labelled warning in the US and such combination cannot be used outside of clinical trials.
In an international, open-label, phase III trial (NOAH), 48 
Future Directions
There is growing interest in targeting drug therapies based on specific signalling pathways for personalised medicine, e.g. neratinib, an investigational second-generation tyrosine kinase inhibitor that inhibits both EGFR (HER1) and HER2 signalling, is being assessed for its role in neoadjuvant chemotherapy with paclitaxel and trastuzumab 54 (NCT01008150 or NSABP FB-7 trial). EGFR antagonists, such as cetuximab, are being studied in combination with ixabepilone versus ixabepilone monotherapy (NCT01097642) in the preoperative setting of TNBC. 55 The recent FDA approval of the novel antibody drug conjugate, ado-trastuzmumab emtansine (Kadcyla ® , Genentech Inc., US) is being About 20-40 % of inflammatory breast cancers are triple-negative. 57 TNBC tumours have a highly varied prognosis and clinical outcome, which may be a reflection of the different numbers of subgroups that have been identified through gene expression profiling. 58 Many researchers postulated that the high percentage of TNBC is one of the reasons that inflammatory breast cancer has been associated with a more aggressive clinical course and decreased OS. 59 Recently, Lehmann and colleagues 60 proposed that TNBC can be classified into six or seven subtypes based on differential gene expressions and gene ontologies: has been demonstrated to have a gene expression profile resembling that of hormone receptor-positive tumours, and this signalling pathway may be attributable to the androgen receptor. 61 Furthermore, emerging data suggest that some breast cancer subtypes, including triple-negative tumours, may be sensitive to neoadjuvant dose-dense alkylating agentbased chemotherapy. 62 Of note, the subtypes proposed by Lehmann were validated by a recent study by Masuda and colleagues 63 in 146 TNBC patients. In this study, they demonstrated a statistically significant association between the TNBC subtype and the pCR status (p=0.04379).
The BL1 subtype had the highest pCR rate (52 %) while the BL2 and LAR subtypes had the lowest (0 % and 10 %, respectively) pCR rates. Further studies to investigate whether such molecular subtyping could translate into a long-term clinical benefit for TNBC patients are underway.
Recently, Giachetti and colleagues 64 compared the efficacy of two different neoadjuvant regimens, either a dose-dense cyclophosphamideanthracycline regimen (n=99) or a sequential administration of cyclophosphamide and anthracycline, followed by taxanes (EC-T) regimen (n=168) in a total of 267 patients with locally advanced breast cancers. Although these two regimens showed equivalent pCR (16 and 12 %, respectively), the dose-dense regimen yielded a statistically nonsignificant higher pCR rate than the conventional EC-T (48 % versus 24 %, p=0.087) regimen. Triple-negative tumours represented 23 % and 25 % of cases, respectively. DFS was statistically higher for triplenegative than for non-triple-negative patients (p=0.019). Toxicities associated with the dose-dense regimen were manageable despite pronounced bone marrow toxicity. Thus, dose-dense neoadjuvant chemotherapy may be associated with a favourable survival in TNBC patients. Apparently, more studies are needed for the dose-dense regimens in the locally advanced tumours.
In addition, based on the molecular subtyping proposed by Lehmann as previously discussed, a subset of TNBC depends on androgen signalling for growth (i.e. the molecular apocrine subtype). Drug therapies that inhibit androgen signalling are undergoing clinical trials to investigate their efficacy in this breast cancer subtype. 65 Last but not least, researchers were able to show that although there is limited evidence that a subset of TNBC patients with BRCA1 mutations may be sensitive to cisplatin, neoadjuvant cisplatin therapy cannot be recommended outside of a clinical trial. Multiagent neoadjuvant chemotherapy remains as the current mainstay for therapy of TNBC.
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Summary and Conclusion
Preoperative or neoadjuvant chemotherapy should be considered 
